|DB06413||Armodafinil||Investigated for use/treatment in sleep disorders, obstructive sleep apnea, schizophrenia and schizoaffective disorders, depression, and bipolar disorders.|
|DB08909||Glycerol phenylbutyrate||Glycerol phenylbutyrate is a nitrogen-binding agent for the chronic management of adult and pediatric patients ≥2 years of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. |
|DB11586||Asunaprevir||Asunaprevir is indicated in combination with other agents for the treatment of chronic hepatitis C in adult patients with hepatitis C virus genotypes 1 or 4 and compensated liver cirrhosis.[L2278]
Hepatitis C is a liver disease caused by the hepatitis C virus. The chronic state of this condition accounts for 60-80% of the cases from which the risk of cirrhosis of the liver within 20 years is of around 15-30%.[L2281] The genotype 1 is the most common type of hepatitis C in the United States and the most difficult to treat.[L2282]|
|DB00615||Rifabutin||For the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.|
|DB06201||Rufinamide||Adjunct therapy for treatment of seizures associated with Lennox-Gastaut syndrome. |
|DB04911||Oritavancin||Indicated for the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms.|
|DB00349||Clobazam||For treatment and management of epilepsy and seizures associated with Lennox-Gastaut syndrome, a difficult-to-treat form of childhood epilepsy. |
|DB00949||Felbamate||For use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use.|
|DB09119||Eslicarbazepine acetate||Eslicarbazepine acetate is indicated as adjunctive therapy in the treatment of partial-onset seizures that are not adequately controlled with conventional therapy in epileptic patients. |
|DB01645||Genistein||Currently Genistein is being studied in clinical trials as a treatment for prostate cancer. |
|DB09078||Lenvatinib||Lenvatinib is indicated for the treatment of following conditions.
- Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.
- Treatment of advanced renal cell carcinoma (RCC) in combination with everolimus following one prior antiangiogenic therapy.
- First-line treatment of unresectable hepatocellular carcinoma (HCC).|
|DB06273||Tocilizumab||Indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). It is also indicated for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) and active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older.|
|DB11767||Sarilumab||Indicated for modere to severe reactive RA in adult patients who are irresponsive, respond inadequately or present intolerance to disease-modifying anti-rheumatic drugs (DMARDs) or tumor necrosis factor (TNF) antagonists. It is indicated to be used in combination with methotrexate (MTX) or as a monotherapy when there is intolerance to MTX or MTX administration is inappropriate.|
|DB09036||Siltuximab||Siltuximab is indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. Siltuximab did not bind to virally produced IL-6 in a nonclinical study and was therefore not studied in patients with MCD who are HIV or HHV-8 positive.|
|DB00273||Topiramate||Topiramate is indicated for the following conditions:
- Monotherapy for partial onset or primary generalized tonic-clonic seizures in patients over 2 years of age.
- Adjunctive therapy for partial onset seizures or primary generalized tonic-clonic seizures for adult and pediatric patients.
- Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome in patients over 2 years of age.
- Prophylaxis of migraine headache in adults.[FDA label]
A seizure is an abnormal, unregulated electrical discharge occurring in the brain's cortical gray matter. This electrical response produces a transient interruption in the normal brain function which in order produces altered awareness, abnormal sensations, focal involuntary movements or convulsions. The type of seizure can be classified according to the type of onset followed by a type of seizure.[L5548]
A migraine headache is a [ulsating or throbbing pain that can be presented in one of both sides of the head and it can be worsened by external stimuli such as physical activity, light, sounds, and odors.[L5551]
Topiramate has been commonly investigated and used off-label for weight reduction in patients with obesity or diabetes.[A175240]|
|DB11823||Esketamine||This drug is indicated in conjunction with an oral antidepressant for the treatment of treatment-resistant depression (TRD) in adults [FDA label].
Note: Esketamine is not approved as an anesthetic agent. The safety and effectiveness of esketamine as an anesthetic agent have not been established to this date [FDA label]. |
1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.
2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.
3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.
4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.
**Off-label** uses include:
1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.[A179182]|
|DB12015||Alpelisib||Alpelisib is indicated in combination with fulvestrant to treat postmenopausal women, and men, with advanced or metastatic breast cancer.[Label] This cancer must be hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and PIK3CA mutated.[Label] The cancer must be detected by an FDA-approved test following progression on or after an endocrine-based regimen.[Label]|
|DB00745||Modafinil||To improve wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy.|